Yu JX - Search Results

1

The novel HLA-B*55:130 allele, identified by Sanger dideoxy nucleotide sequencing in a Chinese individual.

Yu JX, Zheng ZZ, Du KM, An L, Bi H. Yu JX, et al. HLA. 2023 Jan;101(1):59-60. doi: 10.1111/tan.14796. Epub 2022 Sep 13. HLA. 2023. PMID: 36054328

2

Levels of Soluble CD30 and CD26 and Their Clinical Significance in Patients with Primary Immune Thrombocytopenia.

Wang H, Gu X, Li H, Yin L, Tao W, Yu J, Zhou Q, Mu H, Shen Y, Yao J, Liu L, Bi H, Yang R, Zhou Z. Wang H, et al. Biomed Res Int. 2020 Mar 31;2020:1279371. doi: 10.1155/2020/1279371. eCollection 2020. Biomed Res Int. 2020. PMID: 32337220 Free PMC article.

3

Aberrant Expression of a Proliferation-Inducing Ligand Underlies Autoimmune Mechanisms in Immune Thrombocytopenia.

Hao YF, Bi H, Li HY, Yin LM, Yu JX, Tao W, Mu HL, Yang RC, Zhou ZP, Tai WL. Hao YF, et al. Among authors: yu jx. J Immunol Res. 2021 Jan 30;2021:3676942. doi: 10.1155/2021/3676942. eCollection 2021. J Immunol Res. 2021. PMID: 33564689 Free PMC article.

4

A new treatment strategy for thrombotic thrombocytopenic purpura in developing countries: A single dose rituximab-contained regimen.

Tan Y, Zhu Q, Liu L, Liu Y, Yin L, Yao J, Mu H, Li Y, Yin L, Yu J, Tao W, Wei Y, Bi H, Zhou Z. Tan Y, et al. Thromb Res. 2022 Dec;220:72-74. doi: 10.1016/j.thromres.2022.10.002. Epub 2022 Oct 7. Thromb Res. 2022. PMID: 36272335 No abstract available.

5

Efficacy and safety of high dose recombinant human thrombopoietin in the treatment of immune thrombocytopenia.

Wang X, Bi H, Liu L, Liu Y, Yin L, Yao J, Yu J, Tao W, Wei Y, Li Y, Yin L, Mu H, Du Y, Zhou Z. Wang X, et al. Platelets. 2023 Dec;34(1):2271568. doi: 10.1080/09537104.2023.2271568. Epub 2023 Nov 8. Platelets. 2023. PMID: 37941414 Free article.

6

The role of CD83 in the pathogenesis of immune thrombocytopenia.

Wang X, Zhou Q, Yang W, Bi H, Wang H, Wang Y, Du Y, Liu L, Liu Y, Yin L, Yao J, Yu J, Tao W, Zhou Y, Zhou Z. Wang X, et al. Hematology. 2024 Dec;29(1):2372482. doi: 10.1080/16078454.2024.2372482. Epub 2024 Jul 12. Hematology. 2024. PMID: 38994874 Free article.

7

In leukemia, knock-down of the death inducer-obliterator gene would inhibit the proliferation of endothelial cells by inhibiting the expression of CDK6 and CCND1.

Cao H, Wang L, Geng C, Yang M, Mao W, Yang L, Ma Y, He M, Zhou Y, Liu L, Hu X, Yu J, Shen X, Gu X, Yin L, Shen Z. Cao H, et al. PeerJ. 2022 Feb 1;10:e12832. doi: 10.7717/peerj.12832. eCollection 2022. PeerJ. 2022. PMID: 35178295 Free PMC article.

8

MiR-133 promotes the multidrug resistance of acute myeloid leukemia cells (HL-60/ADR) to daunorubicin.

Liu L, Yu K, Yu J, Tao W, Wei Y. Liu L, et al. Cytotechnology. 2024 Dec;76(6):833-846. doi: 10.1007/s10616-024-00656-9. Epub 2024 Sep 19. Cytotechnology. 2024. PMID: 39435426

9

Characterization of microbiota in acute leukemia patients following successful remission induction chemotherapy without antimicrobial prophylaxis.

Shen Z, Gu X, Cao H, Mao W, Yang L, He M, Zhang R, Zhou Y, Liu K, Wang L, Liu L, Yu J, Yin L. Shen Z, et al. Int Microbiol. 2021 May;24(2):263-273. doi: 10.1007/s10123-021-00163-3. Epub 2021 Feb 18. Int Microbiol. 2021. PMID: 33604753

10

Multiplexed mosaic tumor models reveal natural phenotypic variations in drug response within and between populations.

Yu JX, Suh JM, Popova KD, Garcia K, Joshi T, Culbertson B, Spinelli JB, Subramanyam V, Lou K, Shokat KM, Weissman J, Goodarzi H. Yu JX, et al. bioRxiv [Preprint]. 2024 Dec 16:2024.12.13.628239. doi: 10.1101/2024.12.13.628239. bioRxiv. 2024. PMID: 39763922 Free PMC article. Preprint.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

292 results

Search Page

Filters